Polyethylene Glycol, Sodium Phosphate
Conditions
Brief summary
This study is to compare polyethylene glycol and sodium phosphate for colonic cleansing of colonoscopy.
Interventions
DRUGpolyethylene glycol
All patients should receive dietary guidance, and eat a low-residue diet three days before colonoscopy. For polyethylene glycol group (group P): the day before colonoscopy, 750 mL (1 box) of polyethylene glycol solution should be drunk 2 hours after dinner; the other 1500 ml (2 boxes) of polyethylene glycol solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same juniar clinician, and related indicators were recorded.
DRUGsodium phosphate
All patients should receive dietary guidance, and eat a low-residue diet three days before colonoscopy. For sodium phosphate group (group S), 750 mL (1 box) of sodium phosphate solution should be drunk 2 hours after dinner; and the other 750 mL (1 box) of sodium phosphate solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same clinician, and related indicators were recorded.
Sponsors
Xu Hong
Dong Yang
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Outpatients meet the following criteria: 1) age 18-60 years; 2) BMI 18.9-28; 3) Heart, lung, liver, and kidney function can tolerate colonoscopy; 4) Patients and their families are able to understand and be willing to participate in this clinical study and to sign informed consent
Exclusion criteria
* 1\) colorectal surgery history (except appendectomy); 2) patients with intestinal obstruction, incomplete obstruction, intestinal hemorrhage; 3) patients with renal insufficiency; 4) patients with hirschsprung disease; 5) patients with inflammatory bowel disease during active period, which affects intestinal observation; 6) patients who are bedridden and lose the moving ability ; 7) have a history of severe mental illness; 8) pregnant or lactating women; 9) patients with other clinical conditions considered by some researchers should not participate in the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cleansing quality | during the procedure of colonoscopy | The quality of colon cleansing was assessed by the endoscopist with Boston bowel preparation scale. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the duration of the procedure | during the procedure of colonoscopy | time to cecal intubation and withdrawal time |
| patient tolerance | before the procedure of colonoscopy | patient tolerance about oral laxatives. |
| the degree of difficulty of the procedure | at the end of the procedure of colonoscopy | 6-point scale: extremely easy, easy, fairly easy, fairly difficult, difficult, extremely difficult |
| polyps or other endoscopic lesions | at the end of the procedure of colonoscopy | For polyps or other endoscopic lesions, a histopathologic diagnosis was systematically obtained and recorded |
| patient pain | at the end of the procedure of colonoscopy | (visual analog scale, 0-10). |
Countries
China
Outcome results
None listed